|
2019-10-24 |
2019-10-22 |
B
Purchase
|
H LUNDBECK A S
Large shareholder
|
85,923,561
0.00
USD 0
|
85,923,561
|
0.00
|
USD 0
|
|
|
2019-09-18 |
2019-09-16 |
PS
Planned sale
|
Smith Jeffrey T L
Managing Director
|
32,728
-86.1%
18.44
USD 603,504
|
32,728
-86.1%
|
18.44
|
USD 603,504
|
|
|
2019-04-25 |
2019-04-25 |
PS
Planned sale
|
Benedict Larry
EVP and PAO
|
1,734
-4.2%
13.65
USD 23,662
|
1,734
-4.2%
|
13.65
|
USD 23,662
|
|
|
2019-04-25 |
2019-04-25 |
PS
Planned sale
|
Lavelle Erin
Chief Operating Officer
|
1,434
-24.5%
13.67
USD 19,599
|
1,434
-24.5%
|
13.67
|
USD 19,599
|
|
|
2019-04-25 |
2019-04-25 |
PS
Planned sale
|
Hassler Randal
EVP, Pharmaceutical Ops.
|
1,738
-24.2%
13.85
USD 24,067
|
1,738
-24.2%
|
13.85
|
USD 24,067
|
|
|
2019-04-25 |
2019-04-25 |
PS
Planned sale
|
Bucher James B
EVP & General Counsel
|
1,897
-16.2%
13.85
USD 26,281
|
1,897
-16.2%
|
13.85
|
USD 26,281
|
|
|
2018-12-04 |
2018-12-03 |
PS
Planned sale
|
Smith Jeffrey T L
Managing Director
Officer
|
5,044
-85.9%
13.84
USD 69,826
|
5,044
-85.9%
|
13.84
|
USD 69,826
|
|
|
2018-11-05 |
2018-11-01 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
1,319
-0.5%
13.78
USD 18,170
|
1,319
-0.5%
|
13.78
|
USD 18,170
|
|
|
2018-11-05 |
2018-11-01 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
23,683
-8.8%
13.40
USD 317,419
|
23,683
-8.8%
|
13.40
|
USD 317,419
|
|
|
2018-11-05 |
2018-11-01 |
PS
Planned sale
|
Smith Jeffrey T L
Managing Director
Officer
|
5,040
-85.8%
13.42
USD 67,637
|
5,040
-85.8%
|
13.42
|
USD 67,637
|
|
|
2018-10-03 |
2018-10-01 |
PS
Planned sale
|
Smith Jeffrey T L
Managing Director
Officer
|
2,000
-70.6%
15.97
USD 31,944
|
2,000
-70.6%
|
15.97
|
USD 31,944
|
|
|
2018-10-03 |
2018-10-01 |
PS
Planned sale
|
Smith Jeffrey T L
Managing Director
Officer
|
3,040
-51.8%
15.26
USD 46,385
|
3,040
-51.8%
|
15.26
|
USD 46,385
|
|
|
2018-10-03 |
2018-10-01 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
6,554
-2.6%
15.97
USD 104,692
|
6,554
-2.6%
|
15.97
|
USD 104,692
|
|
|
2018-10-03 |
2018-10-01 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
18,445
-6.9%
15.25
USD 281,314
|
18,445
-6.9%
|
15.25
|
USD 281,314
|
|
|
2018-09-06 |
2018-09-04 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
24,999
-9.3%
17.99
USD 449,680
|
24,999
-9.3%
|
17.99
|
USD 449,680
|
|
|
2018-09-06 |
2018-09-04 |
PS
Planned sale
|
Smith Jeffrey T L
Managing Director
Officer
|
5,040
-85.8%
18.00
USD 90,699
|
5,040
-85.8%
|
18.00
|
USD 90,699
|
|
|
2018-08-02 |
2018-08-01 |
PS
Planned sale
|
Smith Jeffrey T L
Managing Director
Officer
|
980
-54.1%
19.76
USD 19,369
|
980
-54.1%
|
19.76
|
USD 19,369
|
|
|
2018-08-02 |
2018-08-01 |
PS
Planned sale
|
Smith Jeffrey T L
Managing Director
Officer
|
4,060
-69.2%
19.49
USD 79,120
|
4,060
-69.2%
|
19.49
|
USD 79,120
|
|
|
2018-08-02 |
2018-08-01 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
24,999
-9.3%
19.55
USD 488,768
|
24,999
-9.3%
|
19.55
|
USD 488,768
|
|
|
2018-07-03 |
2018-07-02 |
PS
Planned sale
|
Smith Jeffrey T L
Managing Director
Officer
|
12,161
-93.6%
15.49
USD 188,364
|
12,161
-93.6%
|
15.49
|
USD 188,364
|
|
|
2018-07-03 |
2018-07-02 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
24,999
-9.3%
15.48
USD 387,002
|
24,999
-9.3%
|
15.48
|
USD 387,002
|
|
|
2018-06-05 |
2018-06-01 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
Officer
|
4,474
-4.2%
18.24
USD 81,587
|
4,474
-4.2%
|
18.24
|
USD 81,587
|
|
|
2018-06-05 |
2018-06-01 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
Officer
|
18,253
-14.6%
17.74
USD 323,825
|
18,253
-14.6%
|
17.74
|
USD 323,825
|
|
|
2018-06-05 |
2018-06-01 |
PS
Planned sale
|
Smith Jeffrey T L
Managing Director
Officer
|
1,100
-57.0%
18.29
USD 20,115
|
1,100
-57.0%
|
18.29
|
USD 20,115
|
|
|
2018-06-05 |
2018-06-01 |
PS
Planned sale
|
Smith Jeffrey T L
Managing Director
Officer
|
11,061
-85.1%
17.81
USD 197,012
|
11,061
-85.1%
|
17.81
|
USD 197,012
|
|
|
2018-06-05 |
2018-06-01 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
4,799
-1.9%
18.25
USD 87,562
|
4,799
-1.9%
|
18.25
|
USD 87,562
|
|
|
2018-06-05 |
2018-06-01 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
20,200
-7.5%
17.76
USD 358,794
|
20,200
-7.5%
|
17.76
|
USD 358,794
|
|
|
2018-05-18 |
2018-05-16 |
PS
Planned sale
|
Smith Jeffrey T L
Managing Director
Officer
|
12,161
-93.6%
15.03
USD 182,758
|
12,161
-93.6%
|
15.03
|
USD 182,758
|
|
|
2017-11-15 |
2017-11-13 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
|
16,519
-14.2%
10.80
USD 178,486
|
16,519
-14.2%
|
10.80
|
USD 178,486
|
|
|
2017-10-18 |
2017-10-16 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
|
16,520
-14.2%
12.33
USD 203,703
|
16,520
-14.2%
|
12.33
|
USD 203,703
|
|
|
2017-07-18 |
2017-07-18 |
B
Purchase
|
YARNO WENDY L
Non-Executive Director
|
5,000
+inf%
10.00
USD 50,000
|
5,000
+inf%
|
10.00
|
USD 50,000
|
|
|
2017-07-18 |
2017-07-18 |
B
Purchase
|
DOW STEPHEN M
Non-Executive Director
|
25,000
+8.9%
10.00
USD 250,000
|
25,000
+8.9%
|
10.00
|
USD 250,000
|
|
|
2017-06-22 |
2017-06-20 |
PS
Planned sale
|
Smith Jeffrey T L
Sr. VP Translational Medicine
|
585
-41.3%
20.00
USD 11,700
|
585
-41.3%
|
20.00
|
USD 11,700
|
|
|
2017-02-13 |
2017-02-09 |
PS
Planned sale
|
Schatzman Randall C
President and CEO
Executive Director
|
30,000
-20.7%
25.03
USD 750,756
|
30,000
-20.7%
|
25.03
|
USD 750,756
|
|
|
2017-01-20 |
2017-01-18 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
|
1,498
-1.5%
23.10
USD 34,599
|
1,498
-1.5%
|
23.10
|
USD 34,599
|
|
|
2017-01-09 |
2017-01-09 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
|
500
-0.5%
23.00
USD 11,500
|
500
-0.5%
|
23.00
|
USD 11,500
|
|
|
2017-01-09 |
2017-01-06 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
|
6,800
-6.4%
23.02
USD 156,520
|
6,800
-6.4%
|
23.02
|
USD 156,520
|
|
|
2017-01-09 |
2017-01-05 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
|
2,216
-2.2%
23.00
USD 50,972
|
2,216
-2.2%
|
23.00
|
USD 50,972
|
|
|
2016-12-05 |
2016-12-01 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
500
-0.2%
23.62
USD 11,810
|
500
-0.2%
|
23.62
|
USD 11,810
|
|
|
2016-12-05 |
2016-12-01 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
3,136
-1.3%
22.64
USD 71,002
|
3,136
-1.3%
|
22.64
|
USD 71,002
|
|
|
2016-12-05 |
2016-12-01 |
PS
Planned sale
|
Smith Jeffrey T L
Sr. VP Translational Medicine
Officer
|
500
-37.6%
23.62
USD 11,810
|
500
-37.6%
|
23.62
|
USD 11,810
|
|
|
2016-12-05 |
2016-12-01 |
PS
Planned sale
|
Smith Jeffrey T L
Sr. VP Translational Medicine
Officer
|
2,500
-65.3%
22.61
USD 56,518
|
2,500
-65.3%
|
22.61
|
USD 56,518
|
|
|
2016-11-14 |
2016-11-09 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
10,000
-4.0%
30.18
USD 301,839
|
10,000
-4.0%
|
30.18
|
USD 301,839
|
|
|
2016-11-09 |
2016-11-07 |
PS
Planned sale
|
Schatzman Randall C
President and CEO
Executive Director
|
10,000
-8.0%
25.16
USD 251,605
|
10,000
-8.0%
|
25.16
|
USD 251,605
|
|
|
2016-11-03 |
2016-11-01 |
PS
Planned sale
|
Smith Jeffrey T L
Sr. VP Translational Medicine
Officer
|
400
-100.0%
24.88
USD 9,950
|
400
-100.0%
|
24.88
|
USD 9,950
|
|
|
2016-11-03 |
2016-11-01 |
PS
Planned sale
|
Smith Jeffrey T L
Sr. VP Translational Medicine
Officer
|
2,600
-86.7%
24.26
USD 63,082
|
2,600
-86.7%
|
24.26
|
USD 63,082
|
|
|
2016-10-19 |
2016-10-17 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
Officer
|
2,000
-7.1%
27.50
USD 55,000
|
2,000
-7.1%
|
27.50
|
USD 55,000
|
|
|
2016-10-19 |
2016-10-17 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
Officer
|
2,000
-7.1%
27.50
USD 55,005
|
2,000
-7.1%
|
27.50
|
USD 55,005
|
|
|
2016-10-19 |
2016-10-17 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
Officer
|
2,000
-7.1%
27.50
USD 54,993
|
2,000
-7.1%
|
27.50
|
USD 54,993
|
|
|
2016-10-05 |
2016-10-03 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
6,249
-2.5%
31.51
USD 196,888
|
6,249
-2.5%
|
31.51
|
USD 196,888
|
|
|
2016-10-05 |
2016-10-03 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
3,751
-1.5%
31.00
USD 116,263
|
3,751
-1.5%
|
31.00
|
USD 116,263
|
|
|
2016-10-05 |
2016-10-03 |
PS
Planned sale
|
Smith Jeffrey T L
Sr. VP Translational Medicine
Officer
|
702
-100.0%
31.62
USD 22,199
|
702
-100.0%
|
31.62
|
USD 22,199
|
|
|
2016-10-05 |
2016-10-03 |
PS
Planned sale
|
Smith Jeffrey T L
Sr. VP Translational Medicine
Officer
|
2,298
-76.6%
30.99
USD 71,216
|
2,298
-76.6%
|
30.99
|
USD 71,216
|
|
|
2016-10-05 |
2016-10-03 |
PS
Planned sale
|
Schatzman Randall C
President and CEO
Executive Director
|
2,700
-2.3%
31.55
USD 85,189
|
2,700
-2.3%
|
31.55
|
USD 85,189
|
|
|
2016-10-05 |
2016-10-03 |
PS
Planned sale
|
Schatzman Randall C
President and CEO
Executive Director
|
5,481
-4.5%
30.95
USD 169,622
|
5,481
-4.5%
|
30.95
|
USD 169,622
|
|
|
2016-09-06 |
2016-09-01 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
10,000
-4.0%
32.49
USD 324,949
|
10,000
-4.0%
|
32.49
|
USD 324,949
|
|
|
2016-09-06 |
2016-09-01 |
PS
Planned sale
|
Schatzman Randall C
President and CEO
Executive Director
|
10,000
-8.0%
32.48
USD 324,820
|
10,000
-8.0%
|
32.48
|
USD 324,820
|
|
|
2016-09-06 |
2016-09-01 |
PS
Planned sale
|
Smith Jeffrey T L
Sr. VP Translational Medicine
Officer
|
100
-100.0%
33.10
USD 3,310
|
100
-100.0%
|
33.10
|
USD 3,310
|
|
|
2016-09-06 |
2016-09-01 |
PS
Planned sale
|
Smith Jeffrey T L
Sr. VP Translational Medicine
Officer
|
2,900
-96.7%
32.47
USD 94,173
|
2,900
-96.7%
|
32.47
|
USD 94,173
|
|
|
2016-08-17 |
2016-08-15 |
S
Sale
|
Smith Jeffrey T L
Sr. VP Translational Medicine
Officer
|
3,000
-100.0%
31.17
USD 93,512
|
3,000
-100.0%
|
31.17
|
USD 93,512
|
|
|
2016-08-03 |
2016-08-01 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
32
-0.0%
32.54
USD 1,041
|
32
-0.0%
|
32.54
|
USD 1,041
|
|
|
2016-08-03 |
2016-08-01 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
6,394
-2.5%
30.88
USD 197,423
|
6,394
-2.5%
|
30.88
|
USD 197,423
|
|
|
2016-08-03 |
2016-08-01 |
PS
Planned sale
|
Schatzman Randall C
President and CEO
Executive Director
|
16
-0.0%
32.69
USD 523
|
16
-0.0%
|
32.69
|
USD 523
|
|
|
2016-08-03 |
2016-08-01 |
PS
Planned sale
|
Schatzman Randall C
President and CEO
Executive Director
|
4,816
-4.0%
31.68
USD 152,570
|
4,816
-4.0%
|
31.68
|
USD 152,570
|
|
|
2016-08-03 |
2016-08-01 |
PS
Planned sale
|
Schatzman Randall C
President and CEO
Executive Director
|
5,168
-4.1%
30.65
USD 158,420
|
5,168
-4.1%
|
30.65
|
USD 158,420
|
|
|
2016-07-28 |
2016-07-27 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
9,187
-3.7%
30.15
USD 277,023
|
9,187
-3.7%
|
30.15
|
USD 277,023
|
|
|
2016-07-28 |
2016-07-26 |
PS
Planned sale
|
Latham John A
Chief Scientific Officer
Officer
|
813
-0.3%
30.00
USD 24,392
|
813
-0.3%
|
30.00
|
USD 24,392
|
|
|
2016-07-27 |
2016-07-25 |
PS
Planned sale
|
Schatzman Randall C
President and CEO
Executive Director
|
10,000
-8.0%
28.08
USD 280,805
|
10,000
-8.0%
|
28.08
|
USD 280,805
|
|
|
2016-06-15 |
2016-06-13 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
Officer
|
200
-0.7%
29.64
USD 5,928
|
200
-0.7%
|
29.64
|
USD 5,928
|
|
|
2016-06-15 |
2016-06-13 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
Officer
|
1,800
-6.0%
28.90
USD 52,012
|
1,800
-6.0%
|
28.90
|
USD 52,012
|
|
|
2016-06-15 |
2016-06-13 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
Officer
|
100
-0.4%
29.60
USD 2,960
|
100
-0.4%
|
29.60
|
USD 2,960
|
|
|
2016-06-15 |
2016-06-13 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
Officer
|
1,900
-6.3%
28.89
USD 54,900
|
1,900
-6.3%
|
28.89
|
USD 54,900
|
|
|
2016-06-15 |
2016-06-13 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
Officer
|
100
-0.4%
29.60
USD 2,960
|
100
-0.4%
|
29.60
|
USD 2,960
|
|
|
2016-06-15 |
2016-06-13 |
PS
Planned sale
|
Litton Mark James
Chief Business Officer
Officer
|
1,900
-6.3%
28.90
USD 54,903
|
1,900
-6.3%
|
28.90
|
USD 54,903
|
|
|
2016-06-07 |
2016-06-03 |
S
Sale
|
Smith Jeffrey T L
Sr. VP Translational Medicine
Officer
|
1,000
-100.0%
31.83
USD 31,827
|
1,000
-100.0%
|
31.83
|
USD 31,827
|
|
